Tenax Therapeutics Inc
TENX
View Detailed Chart
14.010USD
-0.960-6.41%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
512.24Market Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-6.41%
5 Days
-2.03%
1 Month
+16.75%
6 Months
+92.31%
Year to Date
+14.93%
1 Year
+115.87%
View Detailed Chart
TradingKey Stock Score of Tenax Therapeutics Inc
Currency: USD Updated: 2026-03-27Key Insights
Tenax Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 11 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 28.75.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Tenax Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Tenax Therapeutics Inc Highlights
StrengthsRisks
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -11.11, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 6.62M shares, increasing 23.20% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 125.58K shares of this stock.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
28.750
Target Price
+92.05%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Tenax Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Tenax Therapeutics Inc Info
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Ticker SymbolTENX
CompanyTenax Therapeutics Inc
CEOGiordano (Christopher T)
Websitehttp://www.tenaxthera.com/
Related Instruments
-1.16%
-0.37%
+1.36%
+5.68%
-0.69%
+0.95%
+0.45%
-1.22%
-0.40%
+0.67%
-2.98%
+0.25%
+0.57%
+0.60%
-2.33%
0.00%
-0.94%
-0.66%
-0.24%
+1.11%Popular Symbols
246.650
-6.240 (-2.47%)
165.060
-2.460 (-1.47%)
66636.600
+52.550 (+0.08%)
251.665
-21.685 (-7.93%)
2023.650
+23.650 (+1.18%)
355.270
-16.840 (-4.53%)
4510.490
+17.970 (+0.40%)
104.222
+3.613 (+3.59%)
1.146
-0.005 (-0.40%)
159.718
-0.534 (-0.33%)
